Basis: Current FMP quote-based enterprise value / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/FCF ratio is N/A as of 2026-10-06T13:30:37.797Z.
Calculation as of: 2026-10-06T13:30:37.797Z.
Quote observation: 2026-10-06T13:30:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 2c805ffacfcdae638738386c116dc6e6f159143ed75419b2c785d409d5d1ab78
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/FCF RATIO
N/A
Market Cap
$25.61M
EV/FCF Ratio
N/A
TTM Avg
248.89x
3Y Avg
248.89x
5Y Avg
248.89x
Market Cap
$22.00M
EV/FCF Ratio
4.24x
TTM Avg
11.24x
3Y Avg
10.04x
5Y Avg
10.04x
| NAME | MARKET CAP | EV/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Atossa Therapeutics, Inc. (ATOS) | $24.54M | N/A | N/A | N/A | N/A |
| Kyntra Bio, Inc. (KYNB)vs › | $24.65M | N/A | 104.27x | 104.96x | 131.27x |
| ABVC BioPharma, Inc. (ABVC)vs › | $25.61M | N/A | 248.89x | 248.89x | 248.89x |
| Aytu BioPharma, Inc. (AYTU)vs › | $22.00M | 4.24x | 11.24x | 10.04x | 10.04x |
| GridAI Technologies Corp. (GRDX)vs › | $29.24M | N/A | N/A | N/A | N/A |
| Actuate Therapeutics Inc (ACTU)vs › | $21.29M | N/A | N/A | N/A | N/A |
| aTyr Pharma, Inc. (ATYR)vs › | $28.43M | N/A | N/A | N/A | N/A |
| Cosmos Health Inc. (COSM)vs › | $18.54M | N/A | 14.44x | 40.11x | 40.11x |
| Estrella Immunopharma, Inc. (ESLA)vs › | $18.77M | N/A | N/A | N/A | N/A |
| CervoMed Inc. (CRVO)vs › | $31.11M | N/A | N/A | N/A | N/A |
EV/FCF
N/A
P/FCF
N/A
FCF Yield
N/A
Formula: EV/FCF = Enterprise Value / Free Cash Flow
EV/FCF vs P/FCF:
EV/FCF = Enterprise Value / Free Cash Flow (TTM)
Enterprise value to free cash flow compares total company value to the cash the business generates after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
